J. Mel

发表

Adjuvant docetaxel for high-risk, node-negative breast cancer.

A. Ruíz, A. Lluch, J. Zaluski, 2010, The New England journal of medicine.

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.

A. Lluch, J. Zaluski, M. Martín, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer.

M. González-Barón, M. del Mar Pérez, M. Bolaños, 2004, Urologic oncology.

Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

C. Jara, E. Ciruelos, J. Baena, 2015, Clinical and Translational Oncology.

Phase II randomised trial of raltitrexed–oxaliplatin vs raltitrexed–irinotecan as first-line treatment in advanced colorectal cancer

J. Feliu, A. Pèlegrin, M. González-Barón, 2005, British Journal of Cancer.

Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study.

M. Margelí, M. Martín, E. Carrasco, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma

M. Lázaro, F. Vázquez, G. Alonso, 2009, Cancer Chemotherapy and Pharmacology.

Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.

A. Ruíz, V. Guillem, N. Ribelles, 2007, The Lancet. Oncology.

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

Arrate Plazaola, Emilio Alba, Carmen Crespo, 2008, Journal of the National Cancer Institute.

A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.

A. Salar, A. González, A. Alegre, 2008, Current medical research and opinion.

A Pilot Study of y 1 b Interferon in Combination with Fluorouracil , Leucovorin , and a-2 a-Interferon

Ellen, Robert, Mary, 2005 .

Neo‐adjuvant treatment of infiltrating transitional‐cell carcinoma of the bladder with paclitaxel and cisplatin: A phase II trial

M. Rico, J. Mel, S. Vázquez, 2002, International journal of urology : official journal of the Japanese Urological Association.

Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study.

B. Cirauqui, J. García-Saenz, R. Mesía, 2017, International journal of radiation oncology, biology, physics.

Biweekly docetaxel as second-line chemotherapy of patients with advanced non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 006-00)

M. Lázaro, M. Ramos, G. Alonso, 2004, Anti-cancer drugs.

Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02)

M. Lázaro, M. Ramos, M. Salgado, 2007, Anti-cancer drugs.

A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia

A. González, A. Alegre, J. Mel, 2008 .

Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study

R. López-López, J. Tisaire, M. Constenla, 2007, Cancer Chemotherapy and Pharmacology.

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

J. Mayordomo, A. Ruíz, A. Lluch, 2008, Journal of the National Cancer Institute.

Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer.

E. Gallardo, C. Grande, S. Candamio, 2013, Journal of geriatric oncology.

P1-14-03: AVALUZ Study: First Line with Bevacizumab in Combination with Paclitaxel (P) and Gemcitabine (G) in Patients with HER-2 Negative Recurrent or Metastatic BC: PFS Analysis.

C. Jara, E. Ciruelos, J. Baena, 2011 .